The 20 Best Prostate Cancer Doctors near Houston, TX

Brian Chapin is a Urologist in Houston, Texas. Dr. Chapin is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Daniel Hamstra specializes in prostate cancer and tumors of the brain and spine with a particular focus on understanding patients’ experience both during and after treatment. He is the William T. Butler Professor and Chair of Radiation Oncology at Baylor College of Medicine.Dr. Hamstra has led local and national clinical trials of radiation therapy in prostate cancer. His work has made a substantial impact on the growing understanding and appreciation of patient-reported quality of life after radiation therapy.Dr. Hamstra received a B.A. in Biochemistry from Calvin College in Grand Rapids, Michigan and his medical degree and Ph.D. in Pharmacology from The University of Michigan - Ann Arbor, where he also completed an internship in internal medicine and residency in radiation oncology. Dr. Hamstra is a Diplomat of the American Board of Radiology in Radiation Oncology. He is a member of the American Society of Clinical Oncology, the American Society of Therapeutic Radiation Oncology and the Radiological Society of North America. Dr. Hamstra is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, Familial Prostate Cancer, and Prostatectomy.

Phuoc Tran is a Radiation Oncologist in Houston, Texas. Dr. Tran is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Lung Cancer, Prostatectomy, and Pancreaticoduodenectomy. Dr. Tran is currently accepting new patients.

Osama Mohamad is a Radiation Oncologist in Houston, Texas. Dr. Mohamad is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Anal Cancer, Prostatectomy, and Thrombectomy.

Sumit Subudhi is an Oncologist in Houston, Texas. Dr. Subudhi is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pseudomyxoma Peritonei, Vertebroplasty, and Prostatectomy.

Curtis Pettaway is a Urologist and a Surgical Oncologist in Houston, Texas. Dr. Pettaway is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Penile Cancer, Prostate Cancer, Familial Prostate Cancer, Penectomy, and Lymphadenectomy.

Louis Pisters is a Urologist in Houston, Texas. Dr. Pisters is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Bladder Cancer, Familial Prostate Cancer, Prostatectomy, and Cystectomy.

Chad Tang is a Radiation Oncologist in Houston, Texas. Dr. Tang is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, Prostatectomy, and Orchiectomy.

Seungtaek Choi is a Radiation Oncologist in Houston, Texas. Dr. Choi is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Prostatectomy, and Orchiectomy.

Lisly Chery is a Urologist in Houston, Texas. Dr. Chery has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Malakoplakia, Familial Prostate Cancer, Nephrectomy, and Prostatectomy.

Shalin Shah is a Radiation Oncologist in Houston, Texas. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Laryngeal Cancer, and Pleuropulmonary Blastoma. Dr. Shah is currently accepting new patients.

Melissa Joyner is a Radiation Oncologist in Houston, Texas. Dr. Joyner is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Breast Cancer, Cervical Cancer, Endometrial Cancer, and Angiosarcoma. Dr. Joyner is currently accepting new patients.

Ashish Kamat is a Urologist in Houston, Texas. Dr. Kamat is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Martha Mims, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Martha Mims specializes in Medical Oncology and works at BCM Medicine - Hem/Onc. To make an appointment, please call (713) 798-3750. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted. Dr. Mims is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Hypereosinophilic Syndrome, Essential Thrombocythemia, Non-Hodgkin Lymphoma, and Clear Cell Sarcoma.

Lee Wiederhold is a Radiation Oncologist in Houston, Texas. Dr. Wiederhold is rated as an Experienced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Adenoid Cystic Carcinoma, Laryngeal Cancer, Melanoma, and Angiosarcoma. Dr. Wiederhold is currently accepting new patients.

Mohit Khera, M.D., M.B.A., M.P.H., Associate Professor, is the Director of the Laboratory for Andrology Research at McNair Medical Institute, Baylor College of Medicine. He is also the Medical Director of the Executive Health Program at Baylor. Dr. Khera is a Board-certified urologist specializing in male infertility, male and female sexual dysfunction, and declining testosterone levels in aging men. Dr. Khera's research focuses on the efficacy of botulinum toxin type A in treating Peyronie's disease as well as genetic and epigenetic studies on post-finasteride syndrome patients and testosterone replacement therapy. Dr. Khera is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Hypogonadism, Peyronie Disease, Erectile Dysfunction (ED), Hormone Replacement Therapy (HRT), and Prostatectomy.

Dov Kadmon, M.D., is a Board-certified urologist and Professor of Urology at BCM. His practice is focused on the diagnosis and treatment of prostate cancer. He is an experienced surgeon, who has performed over 1,000 open radical prostatectomies and over 1,000 robotic-assisted (da Vinci) laparoscopic radical prostatectomies. He offers his patients state-of-the-art surgical techniques as well as an operation tailored to each individual's special needs. Dr. Kadmon has an extensive record of prostate cancer research, both basic science and clinical. He is recognized nationally and internationally for his contributions to the field and has published over 150 papers in the medical literature. He was awarded numerous grants by the National Cancer Institute to support his research and has served as a consultant to the NCI on the topic of prostate cancer. Dr. Kadmon is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Prostatectomy, and Vasectomy.

Larry I. Lipshultz, M.D., is Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery. Dr. Lipshultz, who holds the Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone production. He received his medical training at the University of Pennsylvania and received fellowship training at the University of Texas at Houston as the first AUA research scholar. Recognized as a leading expert on men’s health, Dr. Lipshultz is a highly respected author and editor, as well as lecturer. Teacher as well as physician, researcher, writer, and editor, Dr. Lipshultz instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 80 physicians who are now in practice both here and abroad. Dr. Lipshultz is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Peyronie Disease, Hypogonadism, Infertility, Vasectomy, and Hormone Replacement Therapy (HRT).

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Dr. Aihua Edward Yen is an oncologist specializing in genitourinary medical oncology. He is an Assistant Professor of Medicine - Hematology and Oncology at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM). He is also an Instructor of Medicine - Hematology and Oncology Section at BCM and a Urology Oncology specialist at the Bladder Cancer Center at BCM’s Dan L Duncan Comprehensive Cancer Center.Dr. Yen’s clinical interests include: prostate cancer and genitourinary cancers.Dr. Yen received his medical degree from Baylor College of Medicine, where he also completed his residency in internal medicine and a fellowship in hematology and medical oncology.Dr. Yen is board-certified in Medical Oncology by the American Board of Internal Medicine. In addition to English, Dr. Yen speaks Mandarin. Dr. Yen is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Non-Muscle Invasive Bladder Cancer.